NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 286 participants.

Also called NCT06141200

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 286 participants (planned count) (from the registry)
Sponsor
Natural Wellness Egypt (from the registry)
Registry
  • NCT NCT06141200
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06141200. Randomized; quadruple masking; primary purpose treatment. Start 2024-03 (anticipated); primary completion 2025-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial
Condition
Essential Hypertension
Intervention (Drug)
NW Roselle
Intervention (Drug)
Captopril 25Mg Tab
Lead sponsor
Natural Wellness Egypt (class: industry)

Record details

Record id
cardio:ct-nct06141200
Content hash
b18c7e15fb7ca14db85e29faeced80f0d820689583af87f8d831d9f8a4711c0b